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Abstract
Inclusion body myopathy associated with Paget disease and frontotemporal dementia (IBMPFD) is a progressive and usually 
misdiagnosed autosomal dominant disorder. It is clinically characterized by a triad of features: proximal and distal myopathy, 
early onset Paget disease of bone (PDB), and frontotemporal dementia (FTD). It is caused by missense mutations in the valosin-
containing protein (VCP) gene. We describe here the clinical and molecular findings of the first Brazilian family identified with 
IBMPFD. Progressive myopathy affecting the limb girdles was detected by clinical examination followed by muscle biopsy and 
creatine kinase measurement. PDB was suggested after anatomopathological bone examination and FTD was diagnosed 
by clinical, neuropsychological and language evaluations. Brain magnetic resonance revealed severe atrophy of the anterior 
temporal lobes, including the hippocampi. A R93C mutation in VCP was detected by direct sequencing screening in subject W 
(age 62) and in his mother. Four more individuals diagnosed with “dementia” were reported in this family. We also present a 
comprehensive genotype-phenotype correlation analysis of mutations in VCP in 182 patients from 29 families described in the 
literature and show that while IBM is a conspicuously penetrant symptom, PDB has a lower penetrance when associated with 
mutations in the AAAD1 domain and FTD has a lower penetrance when associated with mutations in the Junction (L1-D1) do-
main. Furthermore, the R93C mutation is likely to be associated with the penetrance of all the clinical symptoms of the triad.
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Hereditary inclusion body myopathy associated with 
Paget disease of bone (PDB) and frontotemporal dementia 
(FTD; IBMPFD, MIM 167320) is a rare, highly penetrant, 
progressive and ultimately lethal multisystemic disorder. It 
is characterized by a triad of clinical features: 1) proximal 
and distal muscle weakness due to myopathy; 2) early 
age of onset of PDB, and 3) FTD (1,2). Inclusion body 
myopathy is the most common clinical feature of IBMPFD, 
occurring in about 90% of the patients. The myopathy is of 
the adult-onset type and is characterized by progressive 
distal and proximal muscle weakness initially involving the 
shoulder and hip girdle muscles. It is accompanied by dif-
ficulty to raise the arms, inability to properly ambulate or 
to climb stairs, hand weakness and reduction or absence 
of tendon reflexes, thus resembling limb girdle muscular 
dystrophy (2,3). In IBMPFD the highest levels of creatine 
kinase (CK) are typically present at the early stages of the 
disease. Respiratory and cardiac failure may ultimately 
lead to death (4).
PDB in IBMPFD has a classical distribution, being pres-
ent in the spine, pelvis, scapulae, and cranial bones. Other 
symptoms associated with PDB are long and cranial bone 
deformations, pathological fractures and spine and hip pain. 
Elevated levels of alkaline phosphatase, urine pydridinoline 
and deoxypydridinoline are also common (1,4).
Progressive FTD associated with IBMPFD is character-
ized by language and/or behavioral dysfunction due to im-
paired frontal and temporal lobe functions, with preservation 
of copying, drawing, calculation, and visuospatial function 
together with relative preservation of memory. Problems 
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concerning social and personal behavior, apathy, abulia, 
disinhibition, and absence of insight are common (5). Many 
patients report visual and auditory hallucinations. Drastic 
alterations in the personality such as impairment of social 
conduct, aphasia and emotional blunting have also been 
reported (4).
Other inconspicuous clinical features are cardiomyo-
pathy, hepatic fibrosis, sensorimotor axonal neuropathy, 
and cataracts (6-8).
IBMPFD is inherited as an autosomal-dominant trait. It 
is caused by missense mutations in the valosin-containing 
protein gene (VCP, CDC48, or p97), mapped to chromosome 
9p21-p12, a member of the type II AAA-ATPase (ATPases 
Associated with a variety of Activities) family (9). VCP plays 
fundamental roles in multiple events within the cell such 
as membrane fusion, nuclear envelope reconstruction, 
endoplasmic reticulum-associated degradation, post-mitotic 
Golgi cisternae reassembly, and ubiquitin-proteasome deg-
radation. Until now 14 mutations in the VCP gene have 
been described in more than 150 patients with IBMPFD, 
and most of them are clustered in the N-terminal domain. To 
date no correlation between the genotype and phenotype 
has been observed.
We report the clinical and molecular findings of the 
first Brazilian family identified with IBMPFD and review all 
the previous mutations in VCP reported in the literature, 
including the mutation reported here to determine if the 
penetrance of FTD, PDB and myopathy varies according 
to the location of the mutation. 
Subjects and Methods 
The study was approved by the Ethics Committee of 
the Instituto de Biosciências, Universidade de São Paulo, 
Brazil, and written informed consent was obtained from 
all participants. We obtained clinical evaluation, review of 
records, analysis of CK, muscle biopsy, and molecular tests 
for 1 individual (W) and a pedigree diagram for the family 
(Figure 1). Concerning his deceased mother (N), autopsy 
was not performed, but a molecular test was obtained since 
we had isolated her DNA before her death. 
Genomic DNA was isolated from venous blood and 
mutation screening was performed by direct sequencing 
of PCR products of the coding exons of the VCP gene by 
the Children’s Hospital Boston Division of Genetics service, 
Harvard Medical School, USA. The results were confirmed 
at the Human Genome Research Center, University of São 
Paulo, Brazil.
A comprehensive literature review of the reports contain-
ing both clinical and molecular details of the patients was 
performed. Cases containing isolated IBM, PDB, FTD, or 
combinations of these symptoms were considered. Euler-
Venn diagrams comparing the ratio of each symptom in 
relation to total sample number for mutations occurring in 
different VCP protein domains (CDC48, Linker 1, Junction 
(L1-D1), and AAAD1) were prepared. 
Results 
Clinical and molecular data 
Subject W belongs to a multigenerational family that 
includes 3 deceased individuals with dementia. The patient’s 
mother, N, died at the age of 81 years, with a 20-year his-
tory of progressive dementia. We were unable to evaluate 
these individuals or to have access to detailed clinical data 
about them.
Subject W is a 62-year-old university-graduate man with 
a 7-year history of muscle weakness. Clinical examination 
revealed muscle weakness of the shoulders and arms, 
evident proximal weakness, mild lumbar hyperlordosis, 
and pain in the lower neck. He still walks unaided but has 
difficulty to get up from bed or a chair. Tendon reflexes 
Figure 1. Pedigree structure of the family studied here. Black symbols identify affected individuals and the symbols with question 
marks identify possibly affected individuals. The black arrow indicates the proband.
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are present in both upper and lower limbs. 
Prominent calves were present.
A muscle biopsy of the left quadriceps 
muscle showed irregular fiber size with the 
presence of slight to moderate atrophic fibers. 
About 5% of the fibers had nuclear central-
ization. CK measurements at the age of 56 
years ranged from 284 to 572 U/L (normal 
<100 U/L). 
Pathological bone examination of four 
bone fragments from the L3 vertebral body 
performed when the subject was 56 years 
old presented mosaic irregularity of the ce-
ment lines in two of them, with intratrabecular 
spaces filled with vascular connective tissue, 
suggestive of PDB.
Mild behavioral disturbances and cogni-
tive decline had started with progressive 
reduction of initiative and spontaneity, execu-
tive dysfunction, topographic disorientation, 
and forgetfulness when he was 56 years old. 
A neuropsychological evaluation performed 
three years later revealed impairment of at-
tention and concentration, lack of initiative 
and mild difficulty on a multiple-choice face 
recognition test. When he was 60 years old 
his score in the Mini-Mental State Examina-
tion (MMSE) was 29, a normal score for his 
educational level (10,11). Cerebral magnetic 
resonance done at the age of 60 showed 
severe atrophy of the anterior temporal lobes, 
including the hippocampi, with mild diffuse 
enlargement of the cerebral sulci (Figure 
2A-D). Eighteen months later, executive 
dysfunction had increased and difficulties in 
recognizing friends and well-known people 
were evident, together with loss of interest 
in hobbies. His MMSE score was still 29, but 
mild anomia, moderate verbal and non-verbal 
semantic impairments, and moderate to severe prosopag-
nosia were detected. 
Mutation analysis of the propositus revealed a heterozy-
gous nucleotide transition in exon 3 (c.277C → T) of the 
VCP gene resulting in an arginine substitution with cysteine 
in codon 93 (p.R93C). This substitution is located in the 
double ψ barrel of the N-terminal domain, which could 
potentially affect the VCP ubiquitin binding domain. This 
mutation was also identified in the mother (subject N) of 
the propositus. We were not able to test any other member 
of the family.
Genotype-phenotype correlations
In order to perform this analysis we considered clini-
cal and molecular details of 182 patients from 29 different 
families described in 13 articles (Table 1). One hundred 
and sixty-three (89.6%) of these patients, belonging to 24 
families, have mutations in the CDC48 domain of VCP, 
and 90.8% of these mutations are clustered on exon 5. 
Twelve patients from 3 different families were reported 
with mutations in the Linker 1 domain, whereas 4 and 3 
patients were reported with a mutation on Junction (L1-D1) 
and on the AAAD1 domain, respectively, each belonging 
to one family. 
The manifestation ratio of each symptom of the triad 
may vary depending on the protein domain affected by the 
mutation, as pictured in the Euler-Venn diagrams (Figure 3). 
The genotype-phenotype analysis depending on the protein 
domain containing the mutation shows that IBM is the only 
clinical symptom conspicuously penetrant, with the lowest 
penetrance associated with mutations in the AAAD1 domain 
(66%) and the highest (100%) associated with mutations in 
Figure 2. Magnetic resonance imaging of patient W. Coronal image showing at-
rophy of anterior temporal lobes (A), axial images showing atrophy of the anterior 
and medial temporal lobes (B) including the hippocampi (C), and showing mild 
enlargement of the sulci (D). Yellow arrows point to the areas of interest identified 
above.
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the Linker 1 domain. PDB showed no penetrance associated 
with mutations in the AAAD1 domain, full penetrance when 
associated with Junction (L1-D1) domain and penetrance of 
36 and 33% when associated with mutations in the CDC48 
and in the Linker 1 domains, respectively. Last, FTD was 
absent in patients with mutations in the Junction (L1-D1) 
domain and penetrance varied from 31 to 66% when as-
sociated with mutations in the other domains.
Discussion 
Patient W presents mild progressive myopathy affect-
ing mainly the limb girdles, and PDB with the onset of 
the symptoms approximately at the age of 55 years. Mild 
behavioral disturbances and cognitive impairment started 
to develop at the age of 56 years. This caused progres-
sive FTD with features of both the behavioral variant of 
FTD and of semantic dementia and severe atrophy of the 
anterior temporal lobes, one of the characteristic features 
of semantic dementia (12) previously described in cases 
of IBMPFD (13).
Therefore, the clinical presentation of this patient ful-
fills the clinical criteria for this condition, which includes 
the presence of at least 2 of the symptoms of the triad 
and a suspicious family history. It is noteworthy that the 
clinical diagnosis of this patient took several years to be 
established. Indeed, due to its wide phenotypic variability, 
IBMPFD is frequently misdiagnosed. Amongst the com-
mon misdiagnoses are limb-girdle muscular dystrophy, 
amyotrophic lateral sclerosis, Alzheimer’s disease, or other 
types of frontotemporal lobar degenerations and muscular 
dystrophies. 
It should be noted that topographical disorientation as 
observed in this case is an uncommon complaint in FTD. 
However, since prosopagnosia and landmark agnosia are 
frequently associated by both being related to the ventral 
cortical visual processing stream, it is probable that the 
topographical disorientation manifested by this patient was 
caused by landmark agnosia. 
The best approach to confirm the clinical diagnosis of 
Table 1. Clinical and molecular findings of IBMPFD patients harboring mutations in the valosin-containing protein (VCP) gene.
Mutation Exon Protein 
domain
No. of 
families
No. of affected 
patients 
evaluated
IBM PDB FTD IBM + 
FTD
IBM + 
PDB
PDB + 
FTD
IBM + 
PDB + 
FTD
Ref.
R93C 3 CDC48 1 6 - - 2 1 - 1 2   6
1 1 - - - 1 - - - 13
1 1 - - - - - - 1   8
1 1 - - - - - - 1 Present 
article
R95G 3 CDC48 1 6  4 - - 1   1 - -   9
R155C 5 CDC48 2 30 18 - 1 3   4 - 4   9
1 2 - - - 1   1 - - 14
1 1 - - - 1 - - - 15
1 9  3 - 1 5 - - -   6
R155H 5 CDC48 7 78 27 10 3 9 25 - 4   9
1 7  5 - - -   1 - 1 16
1 1 - - - - - - 1   8
R155P 5 CDC48 1 9  3 - - -   5 - 1   9
G157R 5 CDC48 1 4 - - - -   2 2 - 17
R159H 5 CDC48 1 4 - - - -   4 - -   7
R159C 5 CDC48 1 1 - - - 1 - - - 18
1 2 - - - 1 - - 1 19
R191Q 5 Linker 1 1 4  2 - - 2 - - - 19
1 4  2 - - - - - 2   9
L198W 6 Linker 1 1 4  2 - - -   1 - 1 20
A232E 6 Junction 
(L1-D1)
1 4 - 1 - -   3 - -   9
N387H 10 AAAD1 1 3  1 - 1 1 - - - 20
CDC48, Linker 1, Junction (L1-D1), and AAAD1 are different domains of the VCP protein. IBM = inclusion body myopathy; PDB = 
Paget disease of bone; FTD = frontotemporal dementia.
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IBMPFD is molecular testing for VCP. Indeed, the screen-
ing for mutations in the VCP gene in patient W led to the 
identification of the p.R93C mutation, which was also 
present in his mother. This mutation has been described 
before in other patients with IBMPFD and compromises 
an evolutionarily highly conserved arginine residue in the 
VCP N-terminal domain. Therefore, its pathogenicity is 
unquestionable. 
It is important to point out that the full-blown phenotype 
of IBMPFD involves a triad of clinical features, but each of 
its individual components may have a variable penetrance: 
generally, inclusion body myopathy is present in 80-90% 
Figure 3. A, Representation of the VCP gene showing mutations in individuals with Paget disease and frontotemporal dementia and 
relative positions of functional domains in the protein. Asterisks indicate the location of the mutation in the exon-intron structure where 
exons are represented by cylindrical boxes numbered 1-17. The 5’ and the 3’ untranslated regions are out of the hatched area. B, 
Euler-Venn diagrams in which the area of each circle is in proportion with the ratio of each symptom in relation to total sample number 
for mutations occurring in different VCP protein domains. VCP = valosin-containing protein; IBM = inclusion body myopathy; PDB = 
Paget disease of bone; FTD = frontotemporal dementia.
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